FDA pediatric testing tightened—but rare-disease drugs get broad exemption

What it does

This bill amends federal drug-approval law to strengthen pediatric drug-testing requirements while creating new flexibility for orphan drugs (treatments for rare diseases). It requires pharmaceutical companies to complete pediatric studies before approval, gives them 45 days to respond to FDA noncompliance notices before enforcement, and exempts orphan drugs from pediatric testing unless the FDA determines pediatric data would provide meaningful benefit. The bill also funds NIH pediatric research and directs the FDA to issue guidance and maintain a public list of diseases where pediatric testing is waived.

Why we flagged it

The bill's core function is to strengthen pediatric study requirements and FDA enforcement, but it simultaneously creates a broad exemption for orphan drugs—a carve-out that benefits a specific pharmaceutical segment (rare-disease developers) while potentially reducing pediatric data transparency for that segment.

What the text implies

• The 45-day 'due diligence' response window and requirement to prove 'lack of diligence' before enforcement may create a de facto safe harbor for companies that claim good-faith effort, weakening FDA's ability to compel timely pediatric studies.
• Orphan-drug exemption applies broadly to any indication with orphan designation, not just the rare disease itself—a company could develop a common disease treatment under an orphan-designated indication and avoid pediatric testing, reducing pediatric labeling for conditions that affect many children.
• The 180-day transition period before enforcement begins allows companies to delay compliance without penalty, potentially pushing pediatric studies beyond drug approval.
• FDA's discretion to determine 'meaningful therapeutic benefit' for orphan drugs is undefined and may be subject to industry pressure, creating inconsistent enforcement across rare-disease categories.
• The bill requires a GAO study 4 years post-enactment, but provides no mechanism to revise the orphan-drug exemption based on findings—results may show reduced pediatric data without triggering legislative correction.

Who it affects

Children gain potential access to more pediatric-tested drugs and clearer labeling, but orphan-drug exemptions may reduce pediatric data for rare-disease treatments. The 45-day compliance window and 'due diligence' standard may weaken enforcement against companies that delay or avoid pediatric studies, offsetting transparency gains.

Who stands to gain

• orphan drug developers
• rare disease pharmaceutical companies
• biopharmaceutical firms with pediatric-study compliance costs

Named in the bill

FDA, NIH, HHS Secretary, Comptroller General, House Committee on Energy and Commerce, House Committee on Ways and Means, Senate Committee on Health, Education, Labor, and Pensions, LGND (Ligand Pharmaceuticals), REGN (Regeneron Pharmaceuticals), WST (West Pharmaceutical Services)

Where it stands

1 cosponsor: 1 Republicans.

• Feb 25, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 25, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions.”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 5 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $570,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Jack Reed, the sponsor, reported $1,152,500 in PAC receipts in the 2026 cycle.

• American Academy of Pediatrics — $320,000 on 1 filing
• Harmony Biosciences — $180,000 on 1 filing
• Glaxosmithkline LLC — $50,000 on 1 filing
• Children's Cause for Cancer — $20,000 on 2 filings

Lobbying Disclosure Act filings through Jul 9, 2026. A filing shows who paid to lobby on a bill it names, not what changed.